Amberstone Biosciences and Henlius Enter into Collaboration and License Agreement for Conditionally Activated T-Cell Engagers for Solid Tumors
Why now
Thesis: Early-stage oncology deal, no disclosed economics
Catalyst to watch: Clinical trial initiation or milestone data
Main risk: Preclinical asset fails to reach clinic
Why it matters
Preclinical oncology licensing deals rarely move large-cap pharma; no financial terms disclosed.
Details
IRVINE, Calif., Sept. 24, 2026 /PRNewswire/ -- Amberstone Biosciences, Inc., a preclinical-stage oncology company developing pH-gated, tumor-activated T-cell engagers (TCEs), today announced a collaboration and license agreement with Shanghai Henlius Biotech, Inc., a commercial-stage...
Related assets & topics
Eli Lilly · LLYSources
- prnewswire · 2026-09-24 10:33 UTC